• Dr. Alan Baratz shares his perspectives on how tech giants can hinder innovation in the quantum computing and technology fields
• Op-ed calls for business leaders to think more inclusively about technology investment decisions
• D-Wave is the world’s first commercial supplier of quantum computers, bringing practical quantum solutions to the enterprise today

Alan Baratz, CEO of D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services focused on delivering value to customers via practical quantum applications, recently published an opinion piece to point out how he thinks big tech companies have been stifling innovation for decades. According to Dr. Baratz, innovation flourishes when all companies have a seat at the table (https://ibn.fm/kjTLr).

In his article, the D-Wave CEO outlines three ways he believes these tech giants are hindering innovation.

• Big tech has shown a history of delegitimizing proven technologies that do not align with their narrative. Many companies often use statements to dismiss technologies because they cannot create or have missed out on developing them. By discrediting the capabilities and using misleading language, large companies like IBM attempt to silence smaller technology companies and establish themselves as the only solution. 
• Big tech is neutralizing ‘threats’ by playing on uncertainty. These companies are framing smaller companies as risky, which allows them to dominate entire categories with the promise of their technology “eventually getting there,” despite the smaller company already arriving at proven solutions.
• Big tech heavily influences academia and government. Several large tech companies, including AWS, IBM, Google, and Microsoft, have used research funding for direct product development. Dr. Baratz points out that the purpose of academia is to be open-minded and explore different ideas, not to lock them into building products to benefit the larger organizations funding them.

Dr. Baratz’s article calls for business leaders to think about inclusivity when it comes to technology investments and adoption. He says, “Stay open to different possibilities: Don’t be afraid to engage with new technologies, pursue different proofs of concept, and deploy solutions once their value has been proven. This is where true innovation happens.”

D-Wave is the world’s first commercial supplier of quantum computers and caters to customers, including more than two dozen Forbes Global 2000 customers. Some of these customers include blue-chip industry leaders like Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO and Lockheed Martin.

A collection of customer success stories can be found on the D-Wave website at https://ibn.fm/ijGn3.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

• Fr8Tech demonstrated steady growth in Q2 2023 reporting a 29% increase in revenue and a 93% rise in margin compared to 2022 reporting
• The company projects that it will hit revenues up to $42 million in 2023 – an increase over the previous year at approximately $27 million
• Fr8Tech offers technology solutions that include a freight matching platform for OTR shipping internationally, a dedicated truck services and operations platform, and an LTL freight matching platform in Mexico
• Fr8Tech continues to dedicate its offering to innovative solutions that enhance and innovate the transportation industry and simplify and optimize supply chain processes while facilitating shareholder value

Freight Technologies (NASDAQ: FRGT) (“FR8Tech”), a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the USMCA region, recently reported its financial results for the second quarter of 2023, concluding on June 30, 2023. The company has demonstrated steady growth, achieving a 29% increase in revenue compared to the previous quarter and a 93% rise in margin compared to the same year-to-date period last year (https://ibn.fm/TJmrV).

Fr8Tech projects that during 2023, it will hit revenues between $36 million and $42 million – compared to preliminary 2022 revenues of approximately $26 to $27 million. The company’s freight platform was designed to provide carriers with increased growth opportunities while affording shippers flexibility, visibility, and simplicity for a once complex process of international over-the-road (“OTR”) shipping. Fr8App replaces complex and inefficient brokerage systems with a unified automated process making transportation more efficient and driving growth in the transportation industry through its technological advances.

In addition to its freight matching platform, Fr8App, Fr8Tech also offers a dedicated truck platform, Fr8Fleet, which is a digital platform for enterprise customers to handle dedicated truck services and operations. Fr8Tech also now offers a digital freight matching platform for less-than-truckload (“LTL”) services in Mexico through its Fr8Now platform.

According to the company, the second quarter results included these key financial highlights:

• 29% Quarter-over-Quarter Revenue Growth – Strong revenue growth included a noteworthy 29% increase compared to the previous quarter. This growth highlights Fr8Tech’s strong market positioning and effective execution of its business strategy.
• 93% Year-over-Year Margin Increase – Fr8Tech’s margin saw a significant improvement, recording a 93% increase compared to the second quarter of 2022. The increase in 2023 reflects upon the company’s successful implementation of operational efficiencies and prudent cost management strategies.
• Commitment to Innovation – Fr8Tech remains dedicated to driving innovation within supply chain technology landscapes. The relentless pursuit of novel solutions has contributed to new growth opportunities and improved financial performance for the company.
• Solid Financial Foundation – The company’s financial position continues to provide a foundation to build its future growth initiatives and investment strategies. Fr8Tech continues to focus on generating shareholder value.

“We are excited to report another quarter of strong growth and improved profitability at a time when various players in the freight market are facing severe strain and difficulties. These results underscore the dedication and hard work of our exceptional team, as well as the effectiveness of our strategic initiatives,” Paul Freudenthaler, CFO of Fr8Tech, commented on the company’s reported results. “As we move forward, we remain committed to further enhancing value for our shareholders while continuing to innovate and drive excellence in our industry.”

For more information, visit the company’s website at www.Fr8Technologies.com, and its freight matching platform information website at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

Supply chain professionals, logistics experts, pharmaceutical executives, regulatory affairs specialists, technology and solutions providers, healthcare providers, investors, and government representatives, are all invited to attend the 2nd BioPharma Supply Chain & Logistics Nexus to be held in Philadelphia, PA, October 17-18, 2023. This diverse mix of attendees will get a unique platform for collaboration, knowledge sharing, and networking, ensuring a remarkable event for all those involved in the BioPharma supply chain and logistics ecosystem.

The BioPharma industry has always been a beacon of advancement and unwavering innovation, providing life-saving therapies and medicines to innumerable individuals across the globe. However, it’s important to ensure that these essential medications reach their destination in a timely manner amidst the diverse logistics and supply chain complexities. The 2nd BioPharma Supply Chain & Logistics Nexus addresses these challenges head-on, providing expert strategies and insights to succeed in this ever-evolving landscape.

Forward Bound, Interactive Sessions with Experts

The BioPharma Supply Chain & Logistics Nexus 2023 will be a collaborative gathering of industry experts sharing their valuable experience on the topics of supply chain resilience, sustainability initiatives, regulatory compliance, and global collaboration. It’s an important opportunity for attendees to meet industry titans directly, and explore key tactics to harness the power of automation and technology, avoiding mitigations and ensuring a constant flow of essential pharmaceuticals.

The 2nd Annual BioPharma Supply Chain & Logistics Nexus represents a major milestone in the industry’s ongoing efforts towards excellence. This two-day event promises to empower, enlighten, and engage BioPharma professionals from around the world. Attendees can benefit from the insightful sessions that will focus on cutting-edge technologies and innovations in the BioPharma supply chain and logistics industry.

To learn more, please visit https://ibn.fm/RHORL.

• FRGT, through its growing suite of solutions, is proving to be a formidable B2B cross-border shipping player in the NAFTA region
• Its ambitious efforts have seen the company join AMACARGA while also integrating with Samsara and collaborating with Trucker Tools
• By doing so, FRGT is helping the freight transportation marketplace to move commerce efficiently

Freight Technologies (NASDAQ: FRGT), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, remains committed to helping the freight transportation marketplace to move commerce efficiently. Its recent push for its load-matching solution Fr8App, coupled with notable moves such as its collaboration with Trucker Tools, an automated booking solutions platform, reflects this commitment while pointing to the company’s current direction and plans.

Just recently, a new bill, Assembly AB 316, was tabled in California, proposing that heavy-duty autonomous trucks ought to be manned until such a point where tests conclusively show that these trucks would not be a threat. There has been a push for crewless autonomous trucks, with those against it citing motivations such as an increase in profits, but all “At the risk of public safety and the livelihoods of our trained expert trucking workforce” (https://ibn.fm/DOzc1).

FRGT recognizes these developments, and while it acknowledges that the technology has great potential, notably since it leverages technology as its core product and service, it is still pushing for efficient and cost-effective commerce in the best way it knows how. Through its growing suite of solutions, which include the Fr8App, Fr8Radar, Fr8TMS, Fr8FMS, Fr8Data, and Fr8Fleet, the company is making its mark in the industry, proving to be a formidable B2B cross-border shipping player in the NAFTA region.

Its efforts have seen the company join AMACARGA in a move that will help further expand its capabilities to include maritime services and its legacy freight offerings. These efforts have also seen FRGT’s integration with Samsara, a Connected Operations(TM) Cloud pioneer, making it easy for organizations to access, analyze and act upon the real-time data from tracks, trailers, warehouses, and equipment.

“We remain dedicated to pushing the boundaries of innovation and providing exceptional service, consistently exceeding the expectations of our valued customers,” noted Javier Selgas, FRGT’s CEO (https://ibn.fm/Dv8Oo).

This level of dedication and commitment to providing value to its customers has seen the company grow, both in terms of customer numbers and the number of partners in the current calendar year. In addition, the company is on track to carving out a decent market share in the U.S.-Mexico cross-border freight and the U.S. domestic shipping markets, which currently stand at an estimated $385 billion and $732 billion, respectively.

For more information, visit the company’s website at www.Fr8Technologies.com, and its freight matching platform information website at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Cannabis enthusiasts, investors, decision-makers, and business owners, are invited to attend the 18th BioPharma Clinical Trials Nexus to be held in Philadelphia, PA, October 17-18, 2023. The innovative event is set to ignite the spirit of collaboration that transcends disciplines. and borders. It stands as a paradigm for actionable change in the world of clinical research and pharmaceuticals.

The BioPharma Clinical Trials Nexus will feature thought-provoking seminars and sessions where visionaries will share their ideas and perspectives about the key challenges in clinical research and pharmaceutical development. Led by industry veterans, the seminars will focus on discussing the latest innovations in clinical trial technology. Attendees will get exclusive access to interactive discussions with industry leaders who are equipped with insights to drive innovation in patient-centric trials.

Redefining the Clinical Trials Experience

The BioPharma Clinical Trials Nexus serves as a stimulus of progress, uniting visionaries and industry leaders on a mission to revolutionize the clinical research process. The event promises to provide an environment that fosters meaningful collaborations and important connections. It’s a great opportunity for attendees to take their learning and vision to the next level with interactive sessions led by top industry experts.

The BioPharma Clinical Trials Nexus is committed to bringing long-term change by supporting ongoing creativity in the field of clinical trials. It’s a hub for collaborative research projects and post-conference mentorship programs, driving ongoing innovation and collaboration. Focused on Patient-Centricity, the Nexus underscores the significance of a patient-centric approach in clinical trials. Participants will learn the approach to redefine the clinical trial experience. They will get insights into the latest technological solutions including virtual trial platforms as well as AI-powered data analytics.

To learn more, please visit https://ibn.fm/t8n6m.

GolfLync, seen as one of the hottest and fastest growing new golf apps in social media, is pleased to announce a partnership with golfing sensation Eliezer Paul-Gindiri, nicknamed “Snappy Gilmore,” whose distinctive single-handed golf swing stunned the golfing world in 2021. GolfLync’s many features, including its trademarked Virtual Golf Clubs(TM) (“VGC”), private feeds, group chats, and personalized golf experiences, set it apart as the go-to social network for golfers of all levels.

As Snappy Gilmore stated “Finding players is easy on GolfLync. Having my own Virtual Club allowing my followers access is great.”

#snappygilmore, whose TikTok clip went viral in 2021, has amassed more than 2.7 million followers, 89.2 million Likes, along with a legion of fans who can’t help but try the unique swing for themselves. Snappy is a Nigerian-American amateur golfer whose focus on health and wellness, combined with solid entertainment vibes, has generated ongoing buzz with the PGA Tour, PGA Tour of America, and various charitable causes. In a July 10th 2023, article, Sports Illustrated named Snappy Gilmore as one of “The Top Ten Social Media Stars in Sports.”

As Virtual Golf Clubs(TM) continue to redefine social golfing, GolfLync remains at the forefront of the exciting golfing revolution. Download the GolfLync app for free using the following links:

• Android: GolfLync
• iPhone: ‎GolfLync

About GolfLync:

GolfLync is a leading social networking platform designed exclusively for golfers. With a focus on community-building and user engagement, GolfLync connects golf enthusiasts, fosters vibrant virtual golf clubs and enhances the overall golfing experience. GolfLync is available for download on the Apple App Store and the Google Play Store.

For more information about GolfLync, visit GolfLync, download the app, and connect with community on Facebook, X and LinkedIn.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

Contact:
Investor Relations
InvestorRelations@GolfLync.com
(480) 877-9953

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• RJDG acquires, manages, and grows assets in three stable sectors: healthcare billing and payment technology, specialty construction, and environmental services
• Assets include ioSoft Inc., Silex Holdings Inc., and Earthlinc Environmental Solutions
• RJDG’s management team leverages decades of operational, management, and financial expertise to restructure, manage, and position assets for long-term returns

Diversification is one of the keys to investment success in volatile markets. With that principle in focus, the management team at RJD Green (OTC: RJDG), a holding company, is currently building wealth and generating long-term returns in several resilient markets: healthcare billing and payment technology, specialty construction, and environmental services.

RJDG’s portfolio currently comprises ioSoft Inc., Silex Holdings Inc., and Earthlinc Environmental Solutions. ioSoft Inc., a part of RJDG’s healthcare division, offers secure payment technologies and cloud-based software for healthcare payers and providers. ioSoft’s modular SaaS software seamlessly integrates with existing systems to give companies flexible and scalable solutions for medical billing, electronic payments, and healthcare claims adjudication.

Silex Interiors manufactures, distributes, and installs countertops, cabinets, and related bathroom and kitchen products, addressing a large market that includes residential builders, commercial contractors, and retail customers. RJDG aims to position the company between small retail distributors and larger “big box” stores nationwide through a strategy focused primarily on franchising and internal expansion.

RJDG’s third acquisition, Earthlinc Environmental Solutions, offers waste processing technology to commercial farms via its subsidiary Animal Waste Management. The patented technology, developed with support from the University of Arkansas and the Missouri Department of Natural Resources, transforms liquid, solid, and gas waste into clean, odorless, bacteria-free animal feed while separating and recycling the water for further use on the farm.

RJDG’s management team leverages decades of expertise in all sectors under its divisions. The company is led by CEO and Board Director Ron Brewer, who has diverse public and private sector experience spanning the manufacturing, healthcare, energy, environmental services, technology, real estate, and non-profit sectors. With a proven track record of restructuring companies and positioning them for growth, Mr. Brewer directly oversees the corporate management of all divisions within RJDG.

Jerry Niblett, COO and Board Director of RJDG, brings over 19 years of oil and gas experience, including petrochemical refining, natural gas compression, crude oil pipeline and storage, exploration, and business development of products and services. Prior to joining RJD Green, Mr. Niblett headed a corporate turnaround team as national director of Sunoco Pipeline LP. Under his guidance, Sunoco achieved an EBITDA increase from $37,000,000 to $1,000,000,000 EBITDA in eight years. Mr. Niblett additionally had direct P/L responsibilities for annual expense budgets above $25,000,000 and capital integration initiatives over $500,000,000.

John Rabbitt completes the management team as CFO and Board Director, with a comprehensive background in acquisitions, finance, operations, and strategic planning. Mr. Rabbit played a critical role in the growth of MEI Corporation, in addition to other positions at several Fortune 500 firms such as The Pillsbury Company, PepsiCo, and Ernst and Ernst.

Headquartered in Tulsa, Oklahoma, RJD Green Inc. specializes in acquiring, restructuring, and optimizing assets for growth across three key divisions. The management team brings extensive operational, management, and financial expertise, with a focus on stability in today’s increasingly volatile markets. The company is committed to the sustainable growth of assets under its management for long-term wealth generation and investment returns.

For more information, visit the company’s website at www.RJDGreen.com.

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

• The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate properties comparable to the best in scientific literature to date
• D-Wave has manufactured and tested fluxonium qubits in a two-dimensional circuit geometry, measuring several factors
• D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios, with more than 210 issued U.S. patents, and has published more than 100 peer-reviewed papers in leading scientific journals

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced notable progress in its development of high-coherence qubits, with results expected to have a significant impact on its future quantum technologies. The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate quantum properties comparable to the best in scientific literature to date.

The fluxonium qubit was pioneered by Michel Devoret and his colleagues at Yale University in 2009 and has recently become an attractive candidate for use in next-generation gate model quantum computing architectures. With the industry’s growing interest and D-Wave’s expertise in flux-like quantum technologies, the company explored the use of fluxonium in developing its own technology. D-Wave has manufactured and tested fluxonium qubits in a two-dimensional circuit geometry, measuring several factors.

“These results show that fluxonium is a viable candidate qubit for D-Wave’s gate model quantum computing architectures. Moreover, in doing this work, we have learned that fluxonium can address some of the known shortcomings of competing superconducting gate model qubits,” said Mark Johnson, SVP of quantum technologies and systems products at D-Wave (https://ibn.fm/icFXs). “We believe this will have a significant impact on D-Wave’s hardware development and reinforces our technical leadership by demonstrating that we can design, manufacture, and operate high-coherence fluxonium qubits that are comparable to the best in the world.”

We expect that quantum computing will have broad applicability to computationally complex problems across industries, including manufacturing, life sciences, finance, logistics, and more. D-Wave’s pursuit of practical quantum computing has resulted in its technology being used by more than two dozen Forbes Global 2000 companies and blue-chip industry leaders like Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO and Lockheed Martin.

D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios. The company has more than 210 issued U.S. patents and has published more than 100 peer-reviewed papers in leading scientific journals.

According to data from Hyperion Research, over 80% of enterprises are looking to move forward with quantum computing efforts with increased funding and resources. One-third of respondents plan to invest at least $15 million in quantum efforts – all of which will take place in the next two to three years (https://ibn.fm/K387s). We believe this shows that forward-thinking organizations are beginning to recognize quantum as an opportunity to enhance operations – from finding efficiencies and reducing waste to decreasing time to solution and solving problems that were once abandoned due to their complex nature.

D-Wave is strategically positioned to help its customers achieve value by leveraging quantum computing in practical business applications, due to its use of annealing quantum computers. As one of the few companies offering a full stack of quantum computing systems, software, and services, D-Wave is making strides to enable enterprises, governments, developers, and researchers to access the power of quantum computing, which is a unique attribute for prospective investors.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding expectations of how the results of D-Wave’s progress with fluxonium qubits may impact its future quantum technologies and hardware development, including its gate model program; the conclusion that fluxonium may be a viable candidate qubit for D-Wave’s gate model quantum computing architectures; the broad applicability that quantum computing is expected to have to computationally complex problems across industries; the probability that enterprises will invest in quantum computing and the expected amount of such investments; and the ability of quantum computing to help businesses achieve value and to surpass their competition. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the results of further development of fluxonium qubits by D-Wave; the development by other companies of fluxonium qubits that may surpass D-Wave’s technology; the viability of fluxonium qubits as candidates for D-Wave’s gate model quantum computing architectures; the success of fluxonium qubits in gate model quantum computing architectures, if chosen for such purposes; whether fluxonium continues to address some of the known shortcomings of competing superconducting gate model qubits; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. The company undertakes no duty to update this information unless required by law.

• Mexico has become the United States’ leading international trading partner in recent months amid the country’s ongoing trade war with China
• Coincidental with Mexico’s growth as a nearshore commercial trade partner, the port at Laredo, Texas has become the most lucrative hub for cross-border commerce, recording $28.1 billion during this year’s first quarter
• Freight Technologies (aka Fr8Tech) is dedicated to aiding cross-border commerce through a suite of technological solutions targeting the relatively unorganized cross-border shipping and carrier industry
• Fr8Tech’s flagship platform, Fr8App, draws on artificial intelligence and machine learning technology to help match loads optimally and monitor shipments from origin to final destination

The ongoing trade war between the United States and China is leading to a shift in international commerce sourcing that is manifest in changes to the volume of trade traffic at the United States’ shipping and transport gateways.

U.S. Census Bureau data analyzed by media organization WorldCity and in turn reported last month by FreightWaves.com (https://ibn.fm/wXWD5) indicates that Mexico has been the lead trading partner for the United States during five of the past six months, and that the shift toward nearshoring of automotive parts and vehicles, in particular, has driven the trend.

Mexico’s ascendance as a trading partner coincides with the port at Laredo, Texas emerging as the nation’s most lucrative commercial transfer hub among the nation’s 450 international gateways for trade. FreightWaves reported total commerce through Laredo grew 7.4 percent YOY to $28.1 billion, marking the fourth straight month it has exceeded traffic at the Port of Los Angeles and Chicago’s O’Hare International Airport.

Supply chain innovator Freight Technologies (NASDAQ: FRGT) has steadily expanded its technological platform for aiding cross-border commercial freight transportation networks within the United States-Mexico-Canada Agreement (“USMCA”) trade area formerly known as NAFTA.

Freight Technologies’ flagship solution, Fr8App, was released in its first commercial iteration shortly before the U.S.-China Trade War began in January 2018 over concerns that China was conducting intellectual property theft of U.S. technologies and engaging in “unfair trade practices” (https://ibn.fm/kA1Og).

Fr8App’s products package focuses on the relatively unorganized cross-border commercial freight market on the U.S.-Mexico border, and by extension, the U.S.-Canada border — growing to provide freight-matching and origin-to-destination monitoring services for shippers and carriers that draw on artificial intelligence (“AI”) and machine learning technology (https://ibn.fm/s0hbA).

In recent months, the company integrated an extensive new pool of truck drivers from automated booking solutions platform Trucker Tools’ network of over 315,000 carriers (https://ibn.fm/Zv3bl) and celebrated a contract renewal by multinational insulation manufacturing company K-FLEX that expects to have over 100 trucks per week transporting its products from Mexico to the United States, using Fr8App to help manage the shipments (https://ibn.fm/tP3t2).

“Mexico’s expanding manufacturing base has offered an alternative to producing in China. … The automotive industry is an especially active example of the cross-border manufacturing relationship,” Federal Reserve Bank of Dallas senior business economist Luis Torres told FreightWaves. “A U.S. plant typically produces an intermediate good that is then exported to Mexico where it becomes part of the assembly process before a final good is then imported back into the U.S.”

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.app.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Scinai Immunotherapeutics recently announced the closing of a registered direct offering, raising $1.33 million in gross proceeds
• The company intends to use the net proceed from the offering for, among others, research and development
• On its R&D agenda is the development and commercialization of novel innovative NanoAbs targeting a wide range of diseases with known and validated antibody drug targets
• This strategic approach is expected to shorten development timelines, reduce the budgetary requirements, and increase probability of drug approval
• The company has also expanded into the CDMO business to plug an existing gap in the market, raising recurring revenue as a result

Biopharmaceutical company Scinai Immunotherapeutics (NASDAQ: SCNI) recently raised $1.33 million in gross proceeds from its previously announced registered direct offering of 1,146,522 of its American Depositary Shares (“ADSs”) (or ADS equivalents), which closed September 19. Moreover, in a concurrent private placement, the company issued unregistered warrants to purchase up to 1,146,522 ADSs representing ordinary shares. Each ADS represents 400 ordinary shares and was available at a purchase price of $1.16 per ADS (or ADS equivalent). Scinai intends to use the net proceeds from the offering for, general working capital, general corporate purposes, and research and development (“R&D”) (https://ibn.fm/ccWGG).

The company, which is focused on developing, manufacturing, and commercializing biological products for the treatment of autoimmune and infectious diseases, has in the recent past directed its R&D efforts toward the development and eventual commercialization of novel, innovative alpaca-derived nanosized antibodies (“NanoAbs”), also known as VHH-antibodies.

These efforts are rooted in a strategic research collaboration agreement between Scinai Immunotherapeutics and the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (“MPI”), and the University Medical Center Göttingen (“UMG”), both in Germany for the development of the NanoAbs. Based on the agreement, Scinai has an exclusive option for an exclusive worldwide license at pre-agreed commercial terms for further development and commercialization of each generated NanoAb (https://ibn.fm/CV5XI).

The company recently exercised the exclusive option, signing an exclusive license agreement for the development and commercialization of a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis. Scinai is aggressively advancing the NanoAb preclinical development with the expectation that the IL-17 NanoAb will potentially enter clinical testing in 2024, with ex vivo proof-of-concept studies expected later this year (https://ibn.fm/OPSAU).

NanoAbs exhibit multiple valuable competitive advantages over existing monoclonal antibody (“mAb”) therapies, including stability at high temperatures, potential for more effective and convenient routes of administration, and uniquely strong binding affinity. They have superior specificity and affinity to particular targets, potentially enabling lower doses, hence lowering cost and reducing adverse side effects, if any. Moreover, NanoAbs are hyper-thermostable, a property that prolongs their shelf life and eases storage and distribution. Perhaps most importantly, NanoAbs exhibit potential as ‘biobetter’ therapies for a wide range of diseases with known and validated antibody drug targets, a strategic approach expected to shorten development timelines while increasing the probability of drug approval.

Speaking during an episode of the Test. Optimize. Scale. podcast, Amir explained that the strategic selection of both an antibody-based technology (NanoAbs) and indications with validated antibody drug targets prevents the company from reinventing the wheel (https://ibn.fm/ulg3u). Certain antibodies are already known to generate a good clinical response whenever they are used to attack a target molecule. Thus, according to Reichman, Scinai Immunotherapeutics’ strategic approach is expected to shave off $200 million and seven years of drug development.

In addition to its ongoing R&D and to bolster recurring revenue, the company has rolled out boutique end-to-end Contract Development and Manufacturing Organization (“CDMO”) services under the banner Scinai Bioservices. Intended to serve biotech, pharmaceutical, and alternative protein food tech companies with pilot and clinical process development and manufacturing, the division will leverage SCNI’s cGMP manufacturing facility, state-of-the-art laboratories, and deep pharma experience.

“There is growing demand by small biotech companies seeking high quality, yet affordable CDMO services to accelerate their drug development processes, including cGMP aseptic processing required for manufacturing of clinical batches. Scinai’s state-of-the-art biologics facility and team’s capabilities and extensive experience are a perfect match for these clients,” said Reichman in a press release announcing the finalization of a major rebrand (https://ibn.fm/lsGuY).

The company’s management is optimistic about SCNI’s growth potential and ability to deliver value to its stakeholders. “We have a sharp commercial focus and a pipeline with blockbuster potential, steeped in science, strong leadership, and an expertly designed technological base,” concluded Reichman.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI